STAA Stock Overview
Designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for STAA from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
STAAR Surgical Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$19.03 |
| 52 Week High | US$49.86 |
| 52 Week Low | US$13.50 |
| Beta | 0.75 |
| 1 Month Change | 19.54% |
| 3 Month Change | -18.61% |
| 1 Year Change | -58.18% |
| 3 Year Change | -69.01% |
| 5 Year Change | -49.95% |
| Change since IPO | -19.87% |
Recent News & Updates
Recent updates
Is STAAR Surgical Company (NASDAQ:STAA) Trading At A 37% Discount?
Apr 05
Why Investors Shouldn't Be Surprised By STAAR Surgical Company's (NASDAQ:STAA) 26% Share Price Plunge
Feb 14STAAR Surgical Q4: Ongoing Challenges In China Masks Healthy Growth Elsewhere
Feb 12STAAR Surgical: Growth Story Remains Intact Despite Some Challenges
Jan 31STAAR Surgical Company's (NASDAQ:STAA) Earnings Haven't Escaped The Attention Of Investors
Nov 29Return Trends At STAAR Surgical (NASDAQ:STAA) Aren't Appealing
Oct 24
EVO ICL Technology Transforms Vision Care, Securing Major Growth And Market Share Expansion
Sep 13 STAAR Surgical's record sales and expansion in the diopter curve indicate strong global adoption of EVO ICL technology and potential for increased market share.STAAR Surgical: Expecting A Re-Acceleration In Growth As Investments Materialize
Sep 05Results: STAAR Surgical Company Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 10STAAR Surgical Company's (NASDAQ:STAA) Popularity With Investors Is Clear
Aug 05The Returns At STAAR Surgical (NASDAQ:STAA) Aren't Growing
Jul 12Is There Now An Opportunity In STAAR Surgical Company (NASDAQ:STAA)?
May 27Market Participants Recognise STAAR Surgical Company's (NASDAQ:STAA) Revenues Pushing Shares 30% Higher
Apr 26STAAR Surgical Stock: I Don't See A Great Path Forward, Despite The Recent Surge
Apr 05STAAR Surgical (NASDAQ:STAA) Shareholders Will Want The ROCE Trajectory To Continue
Mar 25STAAR Surgical Company: Potential Buy After Long-Term Valuation Downgrade
Mar 13STAAR Surgical Company (NASDAQ:STAA) Looks Just Right With A 28% Price Jump
Mar 07Is There Now An Opportunity In STAAR Surgical Company (NASDAQ:STAA)?
Jan 31With STAAR Surgical Company (NASDAQ:STAA) It Looks Like You'll Get What You Pay For
Jan 05Returns On Capital Are Showing Encouraging Signs At STAAR Surgical (NASDAQ:STAA)
Nov 30Is There An Opportunity With STAAR Surgical Company's (NASDAQ:STAA) 21% Undervaluation?
Nov 12Is STAAR Surgical Company (NASDAQ:STAA) Potentially Undervalued?
Oct 25Returns On Capital At STAAR Surgical (NASDAQ:STAA) Have Hit The Brakes
Aug 24Are STAAR Surgical Company (NASDAQ:STAA) Investors Paying Above The Intrinsic Value?
Jul 02Is Now The Time To Look At Buying STAAR Surgical Company (NASDAQ:STAA)?
Jun 17Here's Why We Think STAAR Surgical (NASDAQ:STAA) Might Deserve Your Attention Today
May 13A Look At The Fair Value Of STAAR Surgical Company (NASDAQ:STAA)
Mar 26STAAR Surgical (NASDAQ:STAA) Is Looking To Continue Growing Its Returns On Capital
Mar 12Should You Investigate STAAR Surgical Company (NASDAQ:STAA) At US$68.56?
Feb 13Here's Why We Think STAAR Surgical (NASDAQ:STAA) Might Deserve Your Attention Today
Jan 28Calculating The Fair Value Of STAAR Surgical Company (NASDAQ:STAA)
Dec 15The Return Trends At STAAR Surgical (NASDAQ:STAA) Look Promising
Dec 01Shareholder Returns
| STAA | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 5.5% | 1.5% | 2.9% |
| 1Y | -58.2% | 8.3% | 10.0% |
Return vs Industry: STAA underperformed the US Medical Equipment industry which returned 8.3% over the past year.
Return vs Market: STAA underperformed the US Market which returned 10% over the past year.
Price Volatility
| STAA volatility | |
|---|---|
| STAA Average Weekly Movement | 10.9% |
| Medical Equipment Industry Average Movement | 9.2% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: STAA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: STAA's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 1,157 | Steve Farrell | www.staar.com |
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) and laser-based procedures, such as LASIK to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.
STAAR Surgical Company Fundamentals Summary
| STAA fundamental statistics | |
|---|---|
| Market cap | US$942.18m |
| Earnings (TTM) | -US$20.21m |
| Revenue (TTM) | US$313.90m |
3.0x
P/S Ratio-46.6x
P/E RatioIs STAA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STAA income statement (TTM) | |
|---|---|
| Revenue | US$313.90m |
| Cost of Revenue | US$74.32m |
| Gross Profit | US$239.58m |
| Other Expenses | US$259.79m |
| Earnings | -US$20.21m |
Last Reported Earnings
Dec 27, 2024
Next Earnings Date
May 07, 2025
| Earnings per share (EPS) | -0.41 |
| Gross Margin | 76.32% |
| Net Profit Margin | -6.44% |
| Debt/Equity Ratio | 0% |
How did STAA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/04 02:58 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2024/12/27 |
| Annual Earnings | 2024/12/27 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
STAAR Surgical Company is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joanne Wuensch | BMO Capital Markets U.S. (Historical) |
| Michael Gorman | BTIG |
| John Young | Canaccord Genuity |